BEACON THERAPEUTICS
Beacon Therapeutics is an ophthalmic gene therapy company that restores and improves vision and rare retinal diseases that result in blindness.
BEACON THERAPEUTICS
Industry:
Health Care Therapeutics
Founded:
2023-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.beacontx.com
Total Employee:
51+
Status:
Active
Contact:
+1 386 462 2204
Email Addresses:
[email protected]
Total Funding:
290.14 M USD
Technology used in webpage:
Google Maps ReCAPTCHA Google Google Cloud Contact Form 7
Similar Organizations
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Atsena Therapeutics
Atsena Therapeutics is a clinical-stage gene therapy company that develops novel treatments for inherited forms of blindness.
Linnaeus Therapeutics
Linnaeus Therapeutics is a development stage biotech company that develops and commercializes drugs for cancer.
Nanoscope Therapeutics
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight.
NovelMed Therapeutics
NovelMed Therapeutics is a biotechnology company developing novel therapies for orphan and non-orphan diseases.
Remedium Bio
Remedium Bio is a gene therapy company focused on the development of highly innovative treatments for a broad range of diseases.
Ring Therapeutics
Ring Therapeutics company focused on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy.
Current Advisors List
Current Employees Featured
Investors List
Oxford Science Enterprises
Oxford Science Enterprises investment in Series B - Beacon Therapeutics
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Beacon Therapeutics
Syncona Partners LLP
Syncona Partners LLP investment in Series B - Beacon Therapeutics
Advent Life Sciences
Advent Life Sciences investment in Series B - Beacon Therapeutics
TCG Crossover
TCG Crossover investment in Series B - Beacon Therapeutics
University of Oxford
University of Oxford investment in Series B - Beacon Therapeutics
Syncona Partners LLP
Syncona Partners LLP investment in Series A - Beacon Therapeutics
Oxford Science Enterprises
Oxford Science Enterprises investment in Series A - Beacon Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-07-24 | Beacon Therapeutics Appoints Lance Baldo, MD as Chief Executive Officer and Thomas Biancardi as Chief Financial Officer |
Official Site Inspections
http://www.beacontx.com Semrush global rank: 3.11 M Semrush visits lastest month: 4.91 K
- Host name: 110.142.242.35.bc.googleusercontent.com
- IP address: 35.242.142.110
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Beacon Therapeutics"
About us - Beacon Therapeutics
Beacon Therapeutics: Pioneering ocular gene therapy to restore vision. Transforming lives through innovative science. Learn more about our groundbreaking approach.See details»
Beacon Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number +1 386 462 2204 Beacon Therapeutics is an ophthalmic gene therapy company that restores and improves vision and rare retinal diseases that result in blindness.See details»
Beacon Therapeutics - Overview, News & Similar companies
Jul 24, 2024 View Beacon Therapeutics (www.beacontx.com) location in Florida, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
Beacon Therapeutics Appoints Lance Baldo, MD as …
Jul 24, 2024 Find out more about Beacon Therapeutics at beacontx.com. Contact: [email protected]. Media: [email protected]. Related news: All news. Beacon Therapeutics Launch. 12 Jun 2023. …See details»
Beacon Therapeutics Ltd. - Drug pipelines, Patents, Clinical trials ...
Explore Beacon Therapeutics Ltd. with its drug pipeline, therapeutic area, technology platform, 2 news, Technology Platform:AAV based gene therapy, Drug:Dry Age-related Macular …See details»
Beacon Therapeutics Raises $170 Million in Series B Funding to …
Jul 3, 2024 Beacon Therapeutics Holdings Limited ('Beacon Therapeutics' or 'the Company'), a leading ophthalmic gene therapy company with a mission to save and restore the vision of …See details»
Beacon Therapeutics - Company Profile & Staff Directory
Discover Beacon Therapeutics company details, including staff directory, contact information, and industry insights. Explore alternatives, competitors, and frequently asked questions to get …See details»
Beacon Therapeutics - VentureRadar
Similar Companies: GenSight Biologics France Publicly Traded GenSight Biologics is a clinical-stage gene therapy company currently focused on discovering, developing and …See details»
Beacon Therapeutics launches with £96 million ($120
Jun 12, 2023 Email: [email protected]. Consilium Strategic Communications: Alex Harrison, Ashley Tapp Email: [email protected] Tel: +44 (0)20 3709 5700. About Beacon …See details»
Beacon Therapeutics launches with £96 million ($120 million) to …
Jun 12, 2023 PRESS RELEASE Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness New …See details»
Beacon Therapeutics Raises $170 Million in Series B Funding to …
Jul 3, 2024 Find out more about Beacon Therapeutics at beacontx.com. Contact: [email protected]. Media: [email protected]. Related news: All news. …See details»
Beacon Therapeutics launches with £96 million ($120 ... - Financial …
Jun 12, 2023 Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness. New leading gene …See details»
Beacon Therapeutics Announces Positive 24-Month Data from …
Oct 15, 2024 Beacon Therapeutics (PRNewsfoto/Beacon Therapeutics) The 24-month data showed a response rate of 57% (4/7) in study eyes treated with a high dose (6.8 E+11 vg/eye) …See details»
Beacon Therapeutics Treats First Patient in VISTA ... - Syncona
Jun 12, 2024 Find out more about Beacon Therapeutics at beacontx.com. Back to News and insights. Related news. 10.07.22. Positive Initial Clinical Data from the B-LIEVE Dose …See details»
Beacon Therapeutics Announces Positive 12-Month Data from
Feb 8, 2024 Find out more about Beacon Therapeutics at beacontx.com. ### Back to News and insights. Related news. 05.06.24. Resolution Therapeutics Announces New Breakthrough …See details»
Careers - Beacon Therapeutics
If you’re passionate about gene therapy and its ability to enhance the lives of patients, then Beacon is a great team to join. We’re a diverse, multi-national team of talented people all …See details»
Beacon Therapeutics Announces Positive 12-Month Data from …
Feb 8, 2024 AGTC-501 was generally safe and well-tolerated and showed robust improvements in visual function at the 12-month analysis; Pivotal Phase 2/3 VISTA trial for AGTC-501 in …See details»
Beacon Therapeutics Announces Positive 24-Month Data from …
Oct 15, 2024 [email protected]. Media: [email protected]. About Beacon Therapeutics Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 …See details»
Abeona Therapeutics and Beacon Therapeutics Announce Non …
Jul 11, 2024 To learn more, please visit www.beacontx.com. Forward-Looking Statements This press release contains certain statements that are forward-looking within the meaning of …See details»